PRODUCTS / DURASERT™ / LATANOPROST
DURASERT™ / LATANOPROST
Durasert™ is a fuly bioerodible implantable delivery device system that can small enough to fit inside the barrel of a 25 gauge needle. We are using this technology to develop a long term sustained release implant of latanoprost, the most commonly prescribed agent for ocular hypertension and glaucoma in the world. The product candidate is designed to be administered by an eye care professional into the subconjunctival space of the eye in a minimally invasive procedure.
A Phase I/II clinical trial designed to assess the safety and efficacy of the implant is underway in patients with elevated intraocular pressure. If successful pSivida plans to advance the product into a multicenter Phase II clinical trial.
The Durasert/latanoprost program is being developed with Pfizer Inc. pursuant to the Research and Development Agreement between the two companies that is focused solely this product.
